Business Context and Reporting Period
This Form 8-K filing by Ironwood Pharmaceuticals, Inc. (IRWD) is dated August 29, 2025, with a signature date of September 3, 2025. The report addresses a corporate governance event regarding the company's listing status on the Nasdaq Global Select Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on regulatory compliance status.
Material Changes
The primary material change reported is the resolution of a listing deficiency. On August 29, 2025, the company received notification from Nasdaq that it has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)). Previously, on May 28, 2025, the company had been notified of non-compliance because its Class A common stock failed to maintain a minimum bid price of $1.00 per share. The company successfully maintained a closing bid price of $1.00 or more for 10 consecutive business days, closing the matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of new risks or contingencies beyond the resolution of the specific listing issue. No unusual items were reported.
Investor Verification Checklist
- Verify the current trading price of IRWD Class A common stock to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the date of the Nasdaq notification letter received on August 29, 2025, via the company's investor relations materials.
- Review the prior Form 8-K filed on June 3, 2025, for details on the initial non-compliance notice.